
Release date: 2026-04-27 15:36:00 Article From: Lucius Laos Recommended: 1
Abrocitinib treats eczema by affecting the immune system, thereby reducing the body's ability to fight infections.Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have been reported in patients taking this drug or other JAK inhibitors, leading to hospitalization or death.Therefore, before starting treatment, your doctor must perform a tuberculosis test; during treatment, you will be closely monitored for any signs of infection.Do not start taking the medication if you currently have any type of infection, or if you have recurrent or persistent infections.Additionally, the risk of developing shingles (herpes zoster) is increased while taking abrocitinib.If you experience fever, sweating, muscle aches, cough, diarrhea, or burning sensation when urinating, tell your doctor immediately.
In individuals aged 50 and older with at least one risk factor for heart disease (such as high blood pressure, diabetes, smoking history), taking JAK inhibitors (including abrocitinib) increases the risk of death, major cardiovascular events (such as heart attack, stroke), and blood clots.In particular, current or past smokers have a higher risk of developing certain cancers, such as lymphoma and lung cancer.Abrocitinib may increase cancer risk by altering how the immune system works.During treatment, your doctor will recommend regular skin checks and sun protection.If you experience persistent chest discomfort, arm or back pain, weakness on one side of the body, slurred speech, sudden shortness of breath, or painful swelling in the legs (signs of a blood clot), seek emergency medical help immediately.
The most common side effects of abrocitinib include: common cold, nausea, headache, cold sores (herpes simplex), elevated blood creatine phosphokinase levels, dizziness, urinary tract infection, fatigue, acne, vomiting, mouth and throat pain, influenza, gastroenteritis, bacterial skin infection, high blood pressure, contact dermatitis, stomach pain, shingles, and decreased platelet count.Additionally, retinal detachment (tearing of the inner lining at the back of the eye) has been reported in patients taking this drug; seek immediate medical attention if you experience sudden vision changes.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2652025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4862024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2722025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2832025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2592025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3062025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2452025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: